Aytu BioPharma (AYTU) Q4 FY26 earnings call

Aytu BioPharma concluded fiscal 2026 with an encouraging fourth quarter, marked by strong momentum in its EXXUA launch and a return to positive adjusted EBITDA. The company is employing a methodical, data-driven approach to commercial investment, focusing on sales force productivity and cash preservation. The legacy ADHD business continues to provide a durable source of cash flow, supporting the strategic build-out of EXXUA.